造血干细胞移植市场－全球产业规模、份额、趋势、机会及预测（按类型、适应症、应用、最终用户、地区和竞争格局划分），2021-2031年

全球造血干细胞移植市场预计将从 2025 年的 30.9 亿美元成长到 2031 年的 46.2 亿美元，复合年增长率为 6.93%。

此治疗领域涉及干细胞输注疗法，旨在恢復免疫力缺乏或骨髓恶性肿瘤患者的骨髓功能。推动这一领域发展的关键因素包括全球血液癌症（如多发性骨髓瘤和白血病）发病率的不断上升，以及供体配型技术的进步，这些进步提高了异基因移植的成功率。根据世界骨髓捐赠者协会（WMDA）2024年的数据，全球骨髓捐赠者登记网络目前涵盖超过4430万份脐带血和志愿者捐赠者，显着扩大了无亲属捐赠者患者的配型途径。

儘管取得了这些积极进展，但移植后併发症的高风险，尤其是移植物抗宿主疾病（GVHD），仍然是市场推广的一大障碍。在这种情况下，供体细胞会侵袭受体组织，需要昂贵且长期的医疗管理，对患者的生活品质产生负面影响。因此，这些临床风险和相关成本阻碍了该技术的广泛应用，尤其是在医疗资源有限的情况下。

市场驱动因素

造血干细胞移植的主要驱动因素是全球骨髓恶性肿瘤发生率的不断上升。进行性血液系统癌症发生率的上升推动了对根治性骨髓重建的临床需求，进而导致成熟医疗机构和新兴医疗机构的移植手术量不断增加。美国癌症协会于2025年1月发布的《2025年癌症事实与数据》报告预测，美国将新增66,890例白血病病例，凸显了有效移植方案的紧迫性。不断扩大的患者群体要求加强移植基础设施建设，并促使捐赠组织扩大移植能力。此外，欧洲血液和骨髓移植协会（EBMT）于2025年2月发布的《2023年造血细胞移植和细胞治疗报告》指出，2023年欧洲医疗中心进行的移植手术数量将达到47,731例，进一步证实了该手术的强劲发展势头。

同时，不匹配和半匹配供体移植技术的重大进步正在消除市场扩张的传统障碍。移植后Cyclophosphamide通讯协定的引入显着提高了部分匹配供体的安全性，使其惠及此前无法获得完全匹配供体的患者。根据国际血液和骨髓移植研究中心于2025年5月发布的《造血细胞移植和细胞治疗的最新活动、趋势和成就》报告，自2020年以来，成人患者接受无关供体不匹配移植的比例翻了一番。这项技术进步降低了对完美基因匹配的依赖，加快了供体筛选速度，直接提升了移植中心的效率，并透过提高移植的可及性推动了市场成长。

市场挑战

移植后併发症，尤其是移植物抗宿主疾病（GVHD）的显着风险，仍是全球造血干细胞移植市场成长的主要障碍。这种不良反应是指捐赠者免疫细胞攻击受体健康组织，造成临床不确定性，并阻碍了此手术的普及。严重的併发症和死亡风险使医护人员和患者都不愿选择移植，尤其是在疾病预后允许采用毒性较小的替代疗法的情况下。因此，市场难以将捐赠者数量的成长趋势转化为与骨髓恶性肿瘤盛行率相符的实际移植量。

此外，在註重成本的医疗环境下，处理这些併发症带来的经济负担严重阻碍了市场扩张。长期免疫抑制治疗和反覆住院治疗移植物抗宿主疾病（GVHD）对许多医疗系统造成了难以承受的经济负担。根据美国卫生资源与服务管理局的数据，CW Bill Young细胞移植计画在2024年协调了7,550例无关供者造血干细胞移植。这一数字意味着大量患者需要昂贵且严格的术后护理。在报销模式严格的地区，这种营运成本实际上限制了移植机会，儘管供体配型技术取得了进步，但仍阻碍了市场潜力。

市场趋势

将 CRISPR-Cas9 和基因编辑技术整合到干细胞疗法中，正从根本上重塑市场格局，将焦点从异体移植转向自体基因修復。这一趋势利用现有的造血干细胞移植基础设施来输注基因修饰细胞，从而无需进行供体配型，并避免了移植物抗宿主疾病 (GVHD) 的相关风险。这种调查方法正迅速走向商业化，尤其是在血红蛋白病领域，有效地将移植中心转变为生物工程疗法的中心。正如 Vertex Pharmaceuticals 在 2025 年 11 月发布的「2025 年第三季财报电话会议」中所述，自 Casgevy 基因编辑疗法开始应用以来，总合39 名患者接受了治疗，这表明该创新治疗方法已得到切实应用。

同时，造血干细胞移植（HSCT）的应用范围正在扩大，涵盖自体免疫疾病和非恶性疾病，拓展了传统肿瘤治疗方法。由于安全性提高以及干细胞重建治癒的潜力，移植中心越来越多地采用HSCT治疗严重的自体免疫疾病和血红蛋白疾病。适应症的扩展正使市场成长不再仅依赖癌症发生率。根据欧洲血液和骨髓移植协会（EBMT）于2025年2月发布的《2023年EBMT造血干细胞移植和细胞治疗报告》，共进行了2558例用于治疗非恶性疾病的异基因移植，这证实了相当一部分市场活动集中在良性疾病领域。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球造血干细胞移植市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（异体移植、自体移植）
  • 根据适应症（白血病、淋巴系统疾病、骨髓瘤等）
  • 透过应用（骨髓移植；週边血干细胞移植；脐带血移植）
  • 依最终用户（医院药局、零售药局、专科诊所）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美造血干细胞移植市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲造血干细胞移植市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区造血干细胞移植市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲造血干细胞移植市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲造血干细胞移植市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球造血干细胞移植市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Pluristem Therapeutics Inc
• Lonza Group AG
• Regen Biopharma Inc.
• Bluebird Bio Inc.
• CellGenix GmbH
• Novartis AG.
• Taiga Biotechnologies Inc.
• Takeda Pharmaceutical Company Limited
• Talaris Therapeutics Inc.
• Merck & Co., Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Hematopoietic Stem Cell Transplantation Market is projected to expand from USD 3.09 Billion in 2025 to USD 4.62 Billion by 2031, registering a CAGR of 6.93%. This therapeutic sector involves stem cell infusion procedures designed to rehabilitate bone marrow functionality in individuals suffering from immune deficiencies or hematological malignancies. Key factors fueling this growth include the increasing global frequency of blood cancers like multiple myeloma and leukemia, coupled with technological strides in donor matching that improve allogeneic transplant success rates. Data from the World Marrow Donor Association in 2024 indicates that the global registry network now encompasses over 44.3 million cord blood units and volunteer donors, significantly broadening access to compatible matches for patients without related donors.

Notwithstanding these positive developments, the market faces a substantial obstacle in the form of high post-transplant complication risks, specifically Graft-Versus-Host Disease. In this condition, donor cells aggressively target the recipient's tissues, requiring costly, long-term medical management and negatively affecting the patient's quality of life. Consequently, these clinical risks and associated costs hinder the widespread adoption of the procedure, particularly within healthcare environments that are sensitive to financial constraints.

Market Driver

The rising global prevalence of hematologic malignancies serves as the central catalyst for the uptake of hematopoietic stem cell transplantation. As aggressive blood cancer rates increase, the clinical demand for curative bone marrow reconstitution intensifies, boosting procedural volumes across both established and developing healthcare sectors. The 'Cancer Facts & Figures 2025' report by the American Cancer Society, released in January 2025, forecasted 66,890 new leukemia diagnoses in the United States, highlighting the urgent requirement for effective transplant solutions. This expanding patient base demands a strengthened transplant infrastructure, prompting providers to increase capacity. Additionally, the '2023 EBMT Report on Hematopoietic Cell Transplantation and Cellular Therapies' from the European Society for Blood and Marrow Transplantation in February 2025 noted 47,731 transplants across European centers in 2023, evidencing strong procedural momentum.

In parallel, major breakthroughs in mismatched and haploidentical donor transplantation methods are eliminating traditional impediments to market expansion. The introduction of post-transplant cyclophosphamide protocols has significantly enhanced the safety of utilizing partially matched donors, thereby extending eligibility to patients who previously lacked a fully matched donor option. According to the 'Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy' report published by the Center for International Blood and Marrow Transplant Research in May 2025, the use of mismatched unrelated donors in adult patients has doubled since 2020. This technical progression decreases reliance on exact genetic matches and expedites donor selection, directly augmenting transplant center throughput and stimulating market growth through improved accessibility.

Market Challenge

The significant threat of post-transplant complications, particularly Graft-Versus-Host Disease (GVHD), remains a formidable obstacle to the growth of the Global Hematopoietic Stem Cell Transplantation Market. This adverse reaction, where the donor's immune cells attack the healthy tissues of the recipient, creates clinical uncertainty that discourages the adoption of the procedure. The potential for severe morbidity or mortality often dissuades both healthcare providers and patients from choosing transplantation, particularly when the disease prognosis permits the use of alternative, less toxic treatments. As a result, the market faces difficulties in translating the increasing availability of donors into actual transplant numbers that match the prevalence of hematological malignancies.

Moreover, the financial burden linked to managing these complications severely hampers market expansion in cost-conscious healthcare settings. The requirement for prolonged immunosuppressive therapies and repeated hospital admissions to address GVHD imposes a fiscal strain that is unsustainable for many healthcare systems. Data from the Health Resources and Services Administration indicates that the C.W. Bill Young Cell Transplantation Program coordinated 7,550 unrelated blood stem cell transplants in 2024, a statistic that highlights the substantial number of patients necessitating expensive, rigorous post-operative care. In areas where reimbursement models are restricted, this operational cost effectively limits transplant accessibility, restricting the market's potential despite progress in donor matching capabilities.

Market Trends

The incorporation of CRISPR-Cas9 and gene editing technologies into stem cell therapies is fundamentally reshaping the market by shifting focus from allogeneic replacement to autologous genetic correction. This trend leverages existing hematopoietic stem cell transplantation infrastructure to administer gene-modified cells, thereby removing the need for donor matching and eliminating the risks associated with Graft-Versus-Host Disease. This methodology is rapidly advancing toward commercialization, especially for hemoglobinopathies, effectively transforming transplant centers into delivery hubs for bio-engineered treatments. As noted in the 'Third Quarter 2025 Financial Results' by Vertex Pharmaceuticals in November 2025, a total of 39 patients have received Casgevy gene-edited therapy infusions since its launch, indicating the concrete adoption of this innovative modality.

Concurrently, the application of HSCT is expanding to include autoimmune and non-malignant disorders, thereby diversifying procedural volumes beyond conventional oncological uses. Transplant centers are increasingly utilizing these procedures to address severe autoimmune diseases and hemoglobinopathies, encouraged by enhanced safety profiles and the curative possibilities offered by stem cell reconstitution. This widening of clinical indications effectively separates market growth from a strict reliance on cancer incidence rates. According to the '2023 EBMT Report on Hematopoietic Cell Transplantation and Cellular Therapies' released by the European Society for Blood and Marrow Transplantation in February 2025, 2,558 allogeneic transplants were performed specifically for non-malignant conditions, underscoring the substantial portion of market activity now focused on benign disorders.

Key Market Players

• Pluristem Therapeutics Inc
• Lonza Group AG
• Regen Biopharma Inc.
• Bluebird Bio Inc.
• CellGenix GmbH
• Novartis AG.
• Taiga Biotechnologies Inc.
• Takeda Pharmaceutical Company Limited
• Talaris Therapeutics Inc.
• Merck & Co., Inc

Report Scope

In this report, the Global Hematopoietic Stem Cell Transplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematopoietic Stem Cell Transplantation Market, By Type

• Allogeneic
• Autologous

Hematopoietic Stem Cell Transplantation Market, By Indication

• Leukemia
• Lymphatic Disorder
• Myeloma
• Other

Hematopoietic Stem Cell Transplantation Market, By Application

• Bone Marrow Transplant; Peripheral Blood Stem Cell Transplant; Cord Blood Transplant

Hematopoietic Stem Cell Transplantation Market, By End User

• Hospital Pharmacy
• Retail Pharmacy
• Specialty Clinics

Hematopoietic Stem Cell Transplantation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hematopoietic Stem Cell Transplantation Market.

Available Customizations:

Global Hematopoietic Stem Cell Transplantation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hematopoietic Stem Cell Transplantation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Allogeneic, Autologous)
  • 5.2.2. By Indication (Leukemia, Lymphatic Disorder, Myeloma, Other)
  • 5.2.3. By Application (Bone Marrow Transplant; Peripheral Blood Stem Cell Transplant; Cord Blood Transplant)
  • 5.2.4. By End User (Hospital Pharmacy, Retail Pharmacy, Specialty Clinics)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Hematopoietic Stem Cell Transplantation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hematopoietic Stem Cell Transplantation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Hematopoietic Stem Cell Transplantation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Hematopoietic Stem Cell Transplantation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Hematopoietic Stem Cell Transplantation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Hematopoietic Stem Cell Transplantation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Hematopoietic Stem Cell Transplantation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hematopoietic Stem Cell Transplantation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Hematopoietic Stem Cell Transplantation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Hematopoietic Stem Cell Transplantation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Hematopoietic Stem Cell Transplantation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hematopoietic Stem Cell Transplantation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Hematopoietic Stem Cell Transplantation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Hematopoietic Stem Cell Transplantation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hematopoietic Stem Cell Transplantation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pluristem Therapeutics Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza Group AG
• 15.3. Regen Biopharma Inc.
• 15.4. Bluebird Bio Inc.
• 15.5. CellGenix GmbH
• 15.6. Novartis AG.
• 15.7. Taiga Biotechnologies Inc.
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. Talaris Therapeutics Inc.
• 15.10. Merck & Co., Inc

16. Strategic Recommendations

17. About Us & Disclaimer